Autolus Therapeutics (AUTL) Misses Q1 EPS by 16c

Autolus Therapeutics (NASDAQ: AUTL) reported Q1 EPS of ($0.24), $0.16 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $10.09 million versus the consensus estimate of $33.4 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Equinor ASA (ADR) (EQNR) PT Lowered to $37 at TD Cowen
• Hormel Foods agrees to sell Brazil's Ceratti brand to Zanchetta